Share on StockTwits

Stock analysts at FBR Capital Markets dropped their price target on shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) from $214.00 to $213.00 in a report issued on Wednesday. FBR Capital Markets’ price target would indicate a potential upside of 56.85% from the company’s current price.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 10.00% on Wednesday, hitting $149.3845. 1,662,561 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a one year low of $76.29 and a one year high of $176.60. The stock has a 50-day moving average of $147.8 and a 200-day moving average of $145.4. The company has a market cap of $8.872 billion and a price-to-earnings ratio of 103.27.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.92 by $0.13. The company had revenue of $291.23 million for the quarter, compared to the consensus estimate of $273.39 million. During the same quarter in the prior year, the company posted $1.43 earnings per share. The company’s quarterly revenue was up 39.8% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals plc – will post $8.07 EPS for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Leerink Swann raised their price target on shares of Jazz Pharmaceuticals plc – from $177.00 to $181.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Finally, analysts at Buckingham Research initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Wednesday, July 23rd. They set a “buy” rating and a $215.00 price target on the stock. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Jazz Pharmaceuticals plc – currently has an average rating of “Buy” and a consensus target price of $174.42.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.